Published in BMJ on February 03, 2012
Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review. PLoS One (2012) 0.81
Pharmaco-mechanic antithrombotic strategies to reperfusion of the infarct-related artery in patients with ST-elevation acute myocardial infarctions. J Cardiovasc Transl Res (2013) 0.80
Coronary thrombus in patients undergoing primary PCI for STEMI: Prognostic significance and management. World J Cardiol (2014) 0.79
Enoxaparin for anticoagulation in patients undergoing percutaneous coronary intervention. BMJ (2012) 0.75
Effect of Heparin Administration during Coronary Angiography on Vascular or Peripheral Complications: A Single-Blind Randomized Controlled Clinical Trial. Iran J Med Sci (2013) 0.75
Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention. Indian Heart J (2016) 0.75
Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions. Curr Cardiol Rev (2012) 0.75
Oral direct thrombin inhibition: a double-edged sword? Heart Lung Vessel (2015) 0.75
Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol (2017) 0.75
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Meta-analysis: principles and procedures. BMJ (1997) 6.87
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation (1998) 2.72
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
EasyMA: a program for the meta-analysis of clinical trials. Comput Methods Programs Biomed (1997) 2.26
Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. Am Heart J (2010) 2.09
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol (2007) 1.75
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol (2006) 1.65
Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. J Interv Cardiol (2009) 1.64
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J (2010) 1.56
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv (2009) 1.56
Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. Eur Heart J (2010) 1.55
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J (2010) 1.55
Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol (2007) 1.51
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv (2010) 1.45
Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. Catheter Cardiovasc Interv (2011) 1.44
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol (2003) 1.44
A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J (2006) 1.41
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med (2008) 1.37
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 1.35
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation (2004) 1.08
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation (2005) 0.98
Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol (1999) 0.91
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol (2002) 0.91
Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol (2003) 0.90
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation (2004) 0.90
Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol (2005) 0.88
Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: A meta-analyis of randomised trials. Thromb Haemost (2009) 0.87
Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. J Am Coll Cardiol (2010) 0.86
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J (2008) 0.85
Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction. Thromb Haemost (2008) 0.83
Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med (2007) 0.82
Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice. Am J Cardiol (2006) 0.82
Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost (2011) 0.81
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Am J Cardiol (2005) 0.81
Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention. Tex Heart Inst J (2009) 0.80
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen. J Thromb Thrombolysis (2008) 0.79
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. Am Heart J (2004) 0.78
Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS). EuroIntervention (2010) 0.78
[Use of a combination of enoxaparin or unfractionated heparin and abciximab during percutaneous coronary interventions: a randomized pilot study]. Rev Esp Cardiol (2002) 0.78
Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. EuroIntervention (2009) 0.77
Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. Am Heart J (2005) 0.77
[Enoxaparin vs. non-fractionated heparin in primary angioplasty of acute myocardial infarction]. Med Intensiva (2009) 0.76
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med (2012) 9.22
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol (2007) 6.15
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med (2015) 5.90
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med (2010) 5.79
Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet (2009) 5.31
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Family presence during cardiopulmonary resuscitation. N Engl J Med (2013) 4.74
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Updated systematic review and meta-analysis of randomized clinical trials on the role of mechanical bowel preparation before colorectal surgery. Ann Surg (2009) 4.66
Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain (2005) 4.59
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med (2012) 4.37
Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS (2006) 3.82
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72
Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology (2008) 3.67
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA (2007) 3.28
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med (2009) 3.23
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Effect of waxy maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients. Anesthesiology (2013) 3.13
Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation (2006) 3.08
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05
STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J (2007) 3.03
Does carotid stent cell design matter? Stroke (2008) 3.02
Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology (2009) 3.01
Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J (2005) 2.94
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Decompressive craniectomy and early cranioplasty for the management of severe head injury: a prospective multicenter study on 147 patients. World Neurosurg (2011) 2.89
Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol (2002) 2.88
Bivalirudin started during emergency transport for primary PCI. N Engl J Med (2013) 2.80
Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. Eur Urol (2012) 2.80
Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA (2009) 2.72
Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68
Fibered confocal fluorescence microscopy (Cell-viZio) facilitates extended imaging in the field of microcirculation. A comparison with intravital microscopy. J Vasc Res (2004) 2.66
Synergistic deleterious effect of hypoxemia and hypovolemia on microcirculation in intestinal villi*. Crit Care Med (2013) 2.65
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke (2007) 2.62
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation (2008) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol (2010) 2.55
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med (2009) 2.49
Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab (2011) 2.48
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29